West Pharmaceutical sets Q2 dividend at $0.21 per share

EXTON, Pa. - West Pharmaceutical Services, Inc. (NYSE: WST), a company specializing in solutions for injectable drug administration, has declared a second-quarter dividend of $0.21 per share. This dividend is scheduled for payment on May 7, 2025, to shareholders who are on record as of April 30, 2025. According to InvestingPro data, WST has maintained dividend payments for 53 consecutive years and has raised its dividend for 32 straight years, demonstrating exceptional commitment to shareholder returns.

The announcement reflects the company’s ongoing commitment to providing value to its shareholders. West Pharmaceutical (TADAWUL:2070), with a workforce of over 10,000 across 50 sites, including 25 manufacturing facilities worldwide, has a significant presence in the healthcare sector, producing over 41 billion components and devices annually.

In the previous fiscal year, the company reported net sales of $2.89 billion. Listed on the New York Stock Exchange under the ticker symbol WST, West Pharmaceutical is also a component of the Standard & Poor’s 500 index.

The company’s role as a key player in the pharmaceutical industry is underscored by its extensive global operations and its focus on ensuring the safe and effective delivery of medications. This dividend payout is a testament to West’s financial health and its ability to generate consistent shareholder returns.

The information in this article is based on a press release statement from West Pharmaceutical Services, Inc.

In other recent news, West Pharmaceutical Services Inc (NYSE:WST). reported its fourth-quarter 2024 earnings, which exceeded analyst expectations with an earnings per share (EPS) of $1.82, surpassing the forecast of $1.72. The company’s revenue for the quarter was $748.8 million, slightly higher than the expected $740.75 million. Despite these positive results, West Pharmaceutical’s stock experienced a notable decline, which analysts attribute to concerns over future growth and margin pressures. The company provided a full-year 2025 EPS guidance of $6.00 to $6.20, alongside net sales guidance ranging from $2.875 billion to $2.905 billion.

KeyBanc Capital Markets revised its price target for West Pharmaceutical to $325 from $470, maintaining an Overweight rating, despite a less optimistic forecast for fiscal year 2025. The company’s focus on expanding GLP-1 production capabilities in Michigan and Dublin is expected to generate an additional $300 million in revenue. West Pharmaceutical’s High Value Products, which account for 57% of revenue, are anticipated to return to mid to high single-digit growth rates. The company also announced a capital expenditure guidance of $275 million, indicating a commitment to long-term growth. KeyBanc analysts remain optimistic about the company’s potential, expecting long-term growth of 7-9% to be met or surpassed in the following year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.